

Special Issue

Radiotherapy for Hepatocellular Carcinoma

Message from the Guest Editor

Traditionally, the role of radiotherapy for hepatocellular carcinoma (HCC) has been limited. However, recent technological innovations such as image-guided radiotherapy, stereotactic body radiotherapy, intensity-modulated radiotherapy, proton therapy, and carbon ion radiotherapy have provided the means to deliver radical doses of radiotherapy to patients with HCC, while avoiding critical normal tissues, providing the opportunity to use radiotherapy for the curative intent treatment of HCC. Radiotherapy can be combined with other systemic treatment modalities, including transarterial chemoembolization (TACE), targeted drug, or immune therapy. This Special Issue stimulates discussion by bringing together expert opinions and novel basic/clinical research on radiotherapy for HCC. Internal radiotherapy as radioembolization, advanced external beam radiotherapy, multimodality approach, and articles analyzing new insights into elucidating the role of radiotherapy in the management of HCC are invited.

Guest Editor

Prof. Dr. Tatsuya Ohno

Gunma University Heavy Ion Medical Center, Gunma University, Showa 3-39-22, Maebashi, Gunma, Japan

Deadline for manuscript submissions

closed (30 September 2020)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/31835

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)